BR0312947A - terapias para insuficiência renal empregando-se interferon-beta - Google Patents

terapias para insuficiência renal empregando-se interferon-beta

Info

Publication number
BR0312947A
BR0312947A BRPI0312947-0A BR0312947A BR0312947A BR 0312947 A BR0312947 A BR 0312947A BR 0312947 A BR0312947 A BR 0312947A BR 0312947 A BR0312947 A BR 0312947A
Authority
BR
Brazil
Prior art keywords
therapies
renal failure
interferon
beta
treatment
Prior art date
Application number
BRPI0312947-0A
Other languages
English (en)
Inventor
Roy R Lobb
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BR0312947A publication Critical patent/BR0312947A/pt

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/50—Queue scheduling
    • H04L47/62—Queue scheduling characterised by scheduling criteria
    • H04L47/6285—Provisions for avoiding starvation of low priority queues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H04L47/215—Flow control; Congestion control using token-bucket
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/0252—Traffic management, e.g. flow control or congestion control per individual bearer or channel
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/0278—Traffic management, e.g. flow control or congestion control using buffer status reports
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W72/00—Local resource management
    • H04W72/20—Control channels or signalling for resource management
    • H04W72/23—Control channels or signalling for resource management in the downlink direction of a wireless link, i.e. towards a terminal
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/02—Processing of mobility data, e.g. registration information at HLR [Home Location Register] or VLR [Visitor Location Register]; Transfer of mobility data, e.g. between HLR, VLR or external networks
    • H04W8/04—Registration at HLR or HSS [Home Subscriber Server]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W72/00—Local resource management
    • H04W72/12—Wireless traffic scheduling

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Databases & Information Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

TERAPIAS PARA INSUFICIêNCIA RENAL EMPREGANDO-SE INTERFERON-BETA. A presente invenção fornece métodos para o tramento, e métodos farmacêuticos para o uso no tratamento de indivíduos mamíferos tendo, ou em risco de desenvolver, glomérulonefrite ou insuficiência renal crónica. Os métodos envolvem a administração de terapêuticos de IFN-<225>.
BRPI0312947-0A 2002-07-17 2003-07-17 terapias para insuficiência renal empregando-se interferon-beta BR0312947A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39639302P 2002-07-17 2002-07-17
PCT/US2003/022440 WO2004006756A2 (en) 2002-07-17 2003-07-17 THERAPIES FOR RENAL FAILURE USING INTERFERON-β

Publications (1)

Publication Number Publication Date
BR0312947A true BR0312947A (pt) 2007-07-10

Family

ID=30116023

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312947-0A BR0312947A (pt) 2002-07-17 2003-07-17 terapias para insuficiência renal empregando-se interferon-beta

Country Status (20)

Country Link
US (1) US20070025965A1 (pt)
EP (1) EP1553971A4 (pt)
JP (2) JP4883665B2 (pt)
KR (2) KR20110053390A (pt)
CN (2) CN1681527A (pt)
AU (1) AU2003256603C1 (pt)
BR (1) BR0312947A (pt)
CA (1) CA2492649A1 (pt)
EA (1) EA009938B1 (pt)
GE (1) GEP20084499B (pt)
IL (2) IL166256A (pt)
IS (1) IS7650A (pt)
MX (1) MXPA05000658A (pt)
NO (1) NO20050827L (pt)
NZ (1) NZ538217A (pt)
PL (1) PL374914A1 (pt)
RS (1) RS20050035A (pt)
UA (1) UA88440C2 (pt)
WO (1) WO2004006756A2 (pt)
ZA (1) ZA200500342B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519840A (ja) 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
RS57549B1 (sr) 2005-08-26 2018-10-31 Ares Trading Sa Proces za pripremu glikoziliranog interferona beta
CA2625978A1 (en) 2005-12-09 2007-06-14 Ares Trading S.A. Method for purifying fsh or a fsh mutant
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2007092252A2 (en) * 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
PL2032134T3 (pl) 2006-05-09 2015-11-30 Genzyme Corp Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów
KR101532369B1 (ko) * 2006-12-11 2015-06-29 삼성전자주식회사 휴대용 단말기의 원격제어 장치 및 방법
EP2594564B1 (en) 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
RU2517345C9 (ru) 2007-10-05 2014-08-20 Гензим Корпорейшн Способ лечения поликистозных заболеваний почек с помощью производных церамида
CA2702448A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying fc-fusion proteins
US8407299B2 (en) * 2007-10-27 2013-03-26 Research In Motion Limited Content disposition system and method for processing message content in a distributed environment
JP5563475B2 (ja) * 2007-12-20 2014-07-30 メルク セローノ ソシエテ アノニム Ｐｅｇインターフェロン−ベータ製剤
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
KR101687039B1 (ko) 2008-10-03 2016-12-15 젠자임 코포레이션 2-아실아미노프로판올형 글루코실세라미드 합성효소 억제제
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
KR101451357B1 (ko) * 2011-02-18 2014-10-15 주식회사 스템디알 Ｓｉｒｔ１ 발현 유도 물질을 포함하는 패혈증 또는 패혈증 쇼크의 예방 또는 치료용 조성물
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
CN112661863A (zh) 2012-11-20 2021-04-16 奥普科生物制品有限公司 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
KR20240006077A (ko) 2016-07-11 2024-01-12 옵코 바이오로직스 리미티드 지속성 응고 인자 vii 및 그 제조 방법
RU2728696C2 (ru) * 2018-12-28 2020-07-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело к интерферону бета-1а человека

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2210622A1 (en) * 1995-11-17 1997-05-29 Toray Industries, Inc. An agent protecting endothelial cells
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
IL142350A0 (en) * 1998-10-16 2002-03-10 Biogen Inc Interferon-beta fusion proteins and pharmaceutical compositions containing the same
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
JP2004536819A (ja) * 2001-06-11 2004-12-09 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２および治療薬を用いた複合治療

Also Published As

Publication number Publication date
NZ538217A (en) 2007-04-27
IL200892A (en) 2014-11-30
JP2005537269A (ja) 2005-12-08
WO2004006756A2 (en) 2004-01-22
UA88440C2 (ru) 2009-10-26
IS7650A (is) 2005-01-14
KR20050021502A (ko) 2005-03-07
RS20050035A (en) 2007-06-04
EP1553971A2 (en) 2005-07-20
EA200500218A1 (ru) 2006-08-25
US20070025965A1 (en) 2007-02-01
KR20110053390A (ko) 2011-05-20
CA2492649A1 (en) 2004-01-22
AU2003256603B2 (en) 2009-07-30
IL166256A0 (en) 2006-01-15
NO20050827L (no) 2005-04-15
IL200892A0 (en) 2010-05-17
MXPA05000658A (es) 2005-08-19
AU2003256603C1 (en) 2010-07-15
GEP20084499B (en) 2008-10-10
JP4883665B2 (ja) 2012-02-22
PL374914A1 (en) 2005-11-14
JP2011144204A (ja) 2011-07-28
CN1681527A (zh) 2005-10-12
IL166256A (en) 2010-11-30
WO2004006756A3 (en) 2004-08-19
ZA200500342B (en) 2006-07-26
EP1553971A4 (en) 2006-07-05
EA009938B1 (ru) 2008-04-28
CN101664545A (zh) 2010-03-10
AU2003256603A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
NO980002L (no) Kaskadepolymerkomplekser, fremgangsmåte for fremstilling, samt farmasöytiske midler inneholdende disse
BR9913645A (pt) Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
BR9711098B1 (pt) compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
FR13C0062I2 (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
ES2128411T3 (es) Inhalador de polvo con soportes de polvo con microestructuras regulares.
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
BRPI0009956B1 (pt) Composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma
CA2427590A1 (en) Evaluating disease progression using magnetic resonance imaging
IS7746A (is) Meðferðir á þrálátum bólgutengdum afmýlunarfjöltaugakvilla með því að nota beta interferon
BR9712816A (pt) Derivados de benzamidina e seu uso como medicamentos com uma atividade antagonista ltb4
PT709097E (pt) Anticorpo anti-fas para a doenca reumatica
BR0314843A (pt) Novo composto
BR0213434A (pt) Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável
BR0315140A (pt) Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação
BR0009334A (pt) Excipiente na forma de pó para o uso emapresentações farmacêuticas sólidas, e, processopara produzir o mesmo
IT1317927B1 (it) Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
WO2004083241A3 (en) Btc-interacting proteins and use thereof
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
BR0212287A (pt) Proteìna de ligação caspase-8, sua preparação e uso
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR9908199A (pt) Derivados de sulfonamida
BR9810387A (pt) (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica
BRPI0416105A (pt) uso da bh4 para o tratamento de doença respiratórias

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.